以类阿片治疗为名的Indivior PLC加入美国Russell 2000 和 3000 指数,表示增长。 Indivior PLC, known for opioid treatments, joins U.S. Russell 2000® and 3000® Indexes, signaling growth.

Indivior PLC,一家专门治疗类阿片使用紊乱治疗的制药公司,于2025年6月30日加入美国Russell 2000 和 3000 指数。 Indivior PLC, a pharmaceutical company specializing in opioid use disorder treatments, was added to the U.S. Russell 2000® and 3000® Indexes on June 30, 2025. 这一举动反映了美国商业的不断增长,其2024年收入的85%来自美国,主要来自其子LOCADE的治疗。 This move reflects its growing U.S. business, where it generated 85% of its 2024 revenue, mainly from its SUBLOCADE® treatment. 投资经理和机构投资者使用的Russell指数以大约10.6万亿美元的资产为基准。 The Russell indexes, used by investment managers and institutional investors, benchmark about $10.6 trillion in assets.